CN114533880B - 用ezh2抑制剂治疗mrto/sccoht的方法 - Google Patents

用ezh2抑制剂治疗mrto/sccoht的方法 Download PDF

Info

Publication number
CN114533880B
CN114533880B CN202210048334.0A CN202210048334A CN114533880B CN 114533880 B CN114533880 B CN 114533880B CN 202210048334 A CN202210048334 A CN 202210048334A CN 114533880 B CN114533880 B CN 114533880B
Authority
CN
China
Prior art keywords
smarca4
ezh2
cancer
tumor
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210048334.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114533880A (zh
Inventor
海克·凯尔哈克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Priority to CN202210048334.0A priority Critical patent/CN114533880B/zh
Publication of CN114533880A publication Critical patent/CN114533880A/zh
Application granted granted Critical
Publication of CN114533880B publication Critical patent/CN114533880B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN202210048334.0A 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法 Active CN114533880B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210048334.0A CN114533880B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562233146P 2015-09-25 2015-09-25
US62/233,146 2015-09-25
US201562252188P 2015-11-06 2015-11-06
US62/252,188 2015-11-06
PCT/US2016/053673 WO2017053930A2 (en) 2015-09-25 2016-09-26 Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
CN201680063541.6A CN108349958B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法
CN202210048334.0A CN114533880B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680063541.6A Division CN108349958B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法

Publications (2)

Publication Number Publication Date
CN114533880A CN114533880A (zh) 2022-05-27
CN114533880B true CN114533880B (zh) 2023-08-22

Family

ID=58387531

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210048334.0A Active CN114533880B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法
CN201680063541.6A Active CN108349958B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680063541.6A Active CN108349958B (zh) 2015-09-25 2016-09-26 用ezh2抑制剂治疗mrto/sccoht的方法

Country Status (12)

Country Link
US (3) US20180296563A1 (https=)
EP (1) EP3352761A4 (https=)
JP (1) JP7013369B2 (https=)
KR (1) KR20180054793A (https=)
CN (2) CN114533880B (https=)
AU (2) AU2016325643B2 (https=)
CA (1) CA2999898A1 (https=)
EA (1) EA201890801A1 (https=)
IL (2) IL258302A (https=)
MX (2) MX2018003663A (https=)
SG (1) SG10201908323TA (https=)
WO (1) WO2017053930A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
JP7013369B2 (ja) * 2015-09-25 2022-02-15 エピザイム，インコーポレイティド Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
US20200129519A1 (en) * 2016-06-08 2020-04-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
JP7324144B2 (ja) * 2017-02-02 2023-08-09 エピザイム，インコーポレイティド 癌処置様式
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS TO TREAT CANCER
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
JP2022527296A (ja) * 2019-03-26 2022-06-01 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー 卵巣の悪性ラブドイド腫瘍および卵巣高カルシウム血症型小細胞がんを処置する方法
CN114555112A (zh) * 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
AU2021280314A1 (en) * 2020-05-28 2022-12-08 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN115786261B (zh) * 2022-11-28 2024-12-06 复旦大学附属妇产科医院 一种卵巢高钙血症型小细胞癌细胞系及其用途
CN119215165B (zh) * 2023-06-29 2026-03-27 复旦大学附属妇产科医院 Plk1抑制剂在制备治疗卵巢高钙血症型小细胞癌的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261890A (zh) * 2010-09-10 2013-08-21 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN103619337A (zh) * 2011-05-16 2014-03-05 乌尔里克·努伯 新型癌症疗法和方法
CN104540500A (zh) * 2012-03-12 2015-04-22 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN104768555A (zh) * 2012-04-13 2015-07-08 Epizyme股份有限公司 用于治疗癌症的联合治疗
CN108349958B (zh) * 2015-09-25 2022-02-15 Epizyme股份有限公司 用ezh2抑制剂治疗mrto/sccoht的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015103431A1 (en) * 2013-12-31 2015-07-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function
MX382033B (es) * 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
KR20180042356A (ko) * 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261890A (zh) * 2010-09-10 2013-08-21 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN103619337A (zh) * 2011-05-16 2014-03-05 乌尔里克·努伯 新型癌症疗法和方法
CN104540500A (zh) * 2012-03-12 2015-04-22 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
CN104768555A (zh) * 2012-04-13 2015-07-08 Epizyme股份有限公司 用于治疗癌症的联合治疗
CN108349958B (zh) * 2015-09-25 2022-02-15 Epizyme股份有限公司 用ezh2抑制剂治疗mrto/sccoht的方法

Also Published As

Publication number Publication date
US20200138825A1 (en) 2020-05-07
KR20180054793A (ko) 2018-05-24
CN108349958B (zh) 2022-02-15
CN108349958A (zh) 2018-07-31
JP2018529698A (ja) 2018-10-11
MX2018003663A (es) 2018-08-14
AU2016325643B2 (en) 2022-07-21
IL280760A (en) 2021-04-29
WO2017053930A2 (en) 2017-03-30
SG10201908323TA (en) 2019-10-30
EA201890801A1 (ru) 2018-09-28
CN114533880A (zh) 2022-05-27
MX2022013390A (es) 2023-01-04
IL258302A (en) 2018-05-31
WO2017053930A3 (en) 2018-04-12
US20180296563A1 (en) 2018-10-18
CA2999898A1 (en) 2017-03-30
EP3352761A2 (en) 2018-08-01
AU2022256115A1 (en) 2022-11-17
US20210121470A1 (en) 2021-04-29
AU2016325643A1 (en) 2018-04-12
EP3352761A4 (en) 2019-04-24
JP7013369B2 (ja) 2022-02-15

Similar Documents

Publication Publication Date Title
CN114533880B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
CN107249591B (zh) 固体药物配制品及其制备方法
US20230181549A1 (en) Use of ezh2 inhibitors for treating cancer
CN110475554B (zh) 用于预防或治疗靶向鞘氨醇1-磷酸受体4的非酒精性脂肪性肝炎的组合物
JP7045985B2 (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
CN108697716A (zh) Ezh2抑制剂及其使用方法
JP2018525414A (ja) 癌を処置するための方法
US11224608B2 (en) Compounds and methods for treating cancer
HK40074912B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法
HK40074912A (en) Methods of treating mrto/sccoht with ezh2 inhibitors
US20110251189A1 (en) Hypoxia targeted compounds for cancer diagnosis and therapy
WO2022271540A1 (en) Inhibitors of dot1l
CN121342873A (zh) 基于N-degron的新型无连接子的微型PROTAC化合物及其用途
WO2021046220A1 (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074912

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant